Vera Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vera Therapeutics (NASDAQ:VERA) reported a Q2 EPS of $(0.62), missing the analyst consensus estimate of $(0.56) by 10.71%. This represents a 34.78% increase in losses compared to $(0.46) per share from the same period last year.
August 08, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vera Therapeutics reported a Q2 EPS of $(0.62), missing the analyst consensus estimate of $(0.56) by 10.71%. This represents a 34.78% increase in losses compared to the same period last year.
The significant miss on EPS estimates and the substantial increase in losses year-over-year are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100